IgA/VCA as a follow-up marker in the monitoring of nasopharyngeal carcinoma.
Titers of IgA/VCA from 92 nasopharyngeal carcinoma (NPC) patients were monitored for 3 to 11 years from the time of diagnosis. The fluctuations in the IgA/VCA titers during follow-up did not correlate with the clinical status of the patients, suggesting that IgA/VCA is of marginal significance in the monitoring of NPC patients during follow-up. In addition, the frequency of recurrence of NPC was independent of presence or absence of elevated IgA/VCA at diagnosis.
Sam
C K
CK
Institute of Advanced Studies, University of Malaya, Kuala Lumpur, Malaysia.
Abu-Samah
A J
AJ
Prasad
U
U
D000957:Antigens, Viral, Tumor / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000276:immunology*; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D009303:Nasopharyngeal Neoplasms / Q000276:immunology*; D011237:Predictive Value of Tests; D012008:Recurrence
D000957:Antigens, Viral, Tumor; D014408:Biomarkers, Tumor; D007070:Immunoglobulin A